Lars Noah

Publications

• "Market Shift Liability" for Generic Drugs: Market Share Theory's Eccentric New Cousin
  13 TEX. A & M L. REV. 1415 (2026) · Texas A&M Law Review · 2026
• Flaws in the Preemption Defense to Liability Claims Against Generic Drug Manufacturers
  79 U. MIAMI L. REV. 431 (2025) · University of Miami Law Review · 2025
• Medication Abortion and the Mails: The Ghost of Anthony Comstock Rides Again?
  41 GA. ST. U. L. REV. 913 (2025) · Georgia State University Law Review · 2025
• Compelled Contraception
  128 W. VA. L. REV. 121 (2025) · West Virginia Law Review · 2025
• “Major Questions” Malarkey: An Arbitrary and Capricious New Doctrine for Vetoing Controversial Agency Rules
  98 ST. JOHN'S L. REV. (2025) · St. John's Law Review · 2025
• Preempting Red State Restrictions on the Use of FDA-Approved Drugs in Gender-Affirming Care?
  2024 UTAH L. REV. (2024) · Utah Law Review · 2024
• Must Courts Recalibrate Tort Law Governing Firearms in Light of the Second Amendment?
  92 U. CIN. L. REV. 412 (2023) · University of Cincinnati Law Review · 2023
• Time to Bite the Bullet? How an Emboldened FDA Could Take Aim at the Firearms Industry
  Connecticut Law Review · 2022
• Censorship is so Last Century: Therapeutic Products, Propaganda, and Compelled Speech
  66 ST. LOUIS U. L.J. (2021) · Saint Louis University Law Journal · 2021
• State Regulatory Responses to the Prescription Opioid Crisis: Too Much to Bear?
  124 DICK. L. REV. 633 (2020) · Dickinson Law Review (2017-Present) · 2020

• Federal Regulatory Responses to the Prescription Opioid Crisis: Too Little, Too Late?
  2019 UTAH L. REV. (2019) · Utah Law Review · 2019
• Doctors on the Take: Aligning Tort Law to Address Drug Company Payments to Prescribers
  66 BUFF. L. REV. 855 (2018) · Buffalo Law Review · 2018
• “Go Sue Yourself!” Imagining Intrapersonal Liability for Negligently Self-Inflicted Harms
  70 FLA. L. REV. 649 (2018) · Florida Law Review · 2018
• Reversal of Fortune: Moving Pharmaceuticals from over-the-Counter to Prescription Status?
  63 VILL. L. REV. 355 (2018) · Villanova Law Review (1956 - ) · 2018
• Product Hopping 2.0: Getting the FDA To Yank Your Original License Beats Stacking Patents
  19 MARQ. INTELL. PROP. L. REV. 161 (2015) · Marquette Intellectual Property Law Review · 2015
• Genetic Modification and Food Irradiation: Are Those Strictly on a Need-to-Know Basis?
  118 DICK. L. REV. 759 (2014) · Dickinson Law Review (1908-2003) · 2014
• Governance by the Backdoor: Administrative Law(lessness?) at the FDA
  93 NEB. L. REV. 89 (2014) · Nebraska Law Review · 2014
• Whatever Happened to the "Frankenfish"?: The FDA's Foot-Dragging on Transgenic Salmon
  65 ME. L. REV. 605 (2013) · Maine Law Review · 2013
• Turn the Beat Around: Deactivating Implanted Cardiac-assist Devices
  39 WM. MITCHELL L. REV. (2013) · William Mitchell Law Review · 2013
• Truth or Consequences?: Commercial Free Speech vs. Public Health Promotion (at the FDA)
  21 HEALTH MATRIX 31 (2011) · Health Matrix: The Journal of Law-Medicine · 2011

• This Is Your Products Liability Restatement on Drugs
  74 BROOK. L. REV. (2009) · Brooklyn Law Review · 2009
• Comfortably Numb: Medicalizing (and Mitigating) Pain-and-Suffering Damages
  42 U. MICH. J. L. REFORM 431 (2009) · University of Michigan Journal of Law Reform · 2009
• Platitudes about Product Stewardship in Torts: Continuing Drug Research and Education
  15 MICH. TELECOMM. & TECH. L. REV. 359 (2009) · Michigan Telecommunications & Technology Law Review · 2009
• The Little Agency That Could (Act with Indifference to Constitutional and Statutory Strictures)
  93 CORNELL L. REV. 901 (2008) · Cornell Law Review · 2008
• Too High a Price for Some Drugs?: The FDA Burdens Reproductive Choice
  44 SAN DIEGO L. REV. 231 (2007) · San Diego Law Review · 2007
• Medical Education and Malpractice: What's the Connection ?
  15 HEALTH MATRIX 149 (2005) · Health Matrix: The Journal of Law-Medicine · 2005
• Triage in the Nation's Medicine Cabinet: The Puzzling Scarcity of Vaccines and Other Drugs
  54 S. C. L. REV. (2003) · South Carolina Law Review · 2003
• Assisted Reproductive Technologies and the Pitfalls of Unregulated Biomedical Innovation
  55 FLA. L. REV. 603 (2003) · Florida Law Review · 2003
• Triage in the Nation's Medicine Cabinet: The Puzzling Scarcity of Vaccines and Other Drugs
  54 S. C. L. REV. (2002) · South Carolina Law Review · 2002
• Divining Regulatory Intent: The Place for a "Legislative History" of Agency Rules
  51 UC L.J. 255 (2000) · UC Law Journal · 2000
• Interpreting Agency Enabling Acts: Misplaced Metaphors in Administrative Law
  41 WM. & MARY L. REV. 1463 (2000) · William & Mary Law Review · 2000

• Pigeonholing Illness: Medical Diagnosis as a Legal Construct
  50 UC L.J. 241 (1999) · UC Law Journal · 1999
• The Executive Line Item Veto and the Judicial Power to Sever: What's the Difference?
  56 WASH. & LEE L. REV. 235 (1999) · Washington and Lee Law Review · 1999
• The FDA's New Policy on Guidelines: Having Your Cake and Eating it Too
  47 CATH. U. L. REV. 113 (1997) · Catholic University Law Review · 1997
• Reconceptualizing Federal Preemption of Tort Claims As the Government Standards Defense
  37 WM. & MARY L. REV. 903 (1996) · William & Mary Law Review · 1996
• Liberating Commercial Speech: Product Labeling Controls and the First Amendment
  47 FLA. L. REV. 63 (1995) · Florida Law Review · 1995
• Sham Petitioning As a Threat to the Integrity of the Regulatory Process
  74 N. C. L. REV. 1 (1995) · North Carolina Law Review · 1995